These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 19014588)

  • 1. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.
    Hadjimichael O; Vollmer T; Oleen-Burkey M;
    Health Qual Life Outcomes; 2008 Nov; 6():100. PubMed ID: 19014588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice.
    Meca-Lallana J; Hernández L; Caminero AB; Girón JM; Cano-Orgaz A; Carcelén-Gadea M; Muñoz D; Durán-Ferreras E; Martín-Hernández J; Sánchez-de la Rosa R;
    Eur Neurol; 2016; 76(1-2):40-7. PubMed ID: 27376845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry.
    Lo AC; Hadjimichael O; Vollmer TL
    Mult Scler; 2005 Feb; 11(1):33-40. PubMed ID: 15732264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: a cross-sectional survey.
    Rinker JR; Salter AR; Walker H; Amara A; Meador W; Cutter GR
    BMJ Open; 2015 Jan; 5(1):e006714. PubMed ID: 25573524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the NARCOMS registry: fatigue assessment.
    Marrie RA; Cutter G; Tyry T; Hadjimichael O; Campagnolo D; Vollmer T
    Mult Scler; 2005 Oct; 11(5):583-4. PubMed ID: 16193897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current approved options for treating patients with multiple sclerosis.
    Rizvi SA; Agius MA
    Neurology; 2004 Dec; 63(12 Suppl 6):S8-14. PubMed ID: 15623672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis.
    Ziemssen T; Hoffman J; Apfel R; Kern S
    Health Qual Life Outcomes; 2008 Sep; 6():67. PubMed ID: 18775064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of immunomodulatory treatment on multiple sclerosis fatigue.
    Metz LM; Patten SB; Archibald CJ; Bakker JI; Harris CJ; Patry DG; Bell RB; Yeung M; Murphy WF; Stoian CA; Billesberger K; Tillotson L; Peters S; McGowan D
    J Neurol Neurosurg Psychiatry; 2004 Jul; 75(7):1045-7. PubMed ID: 15201369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of fatigue and social participation in multiple sclerosis as assessed using two different instruments.
    Salter A; Fox RJ; Tyry T; Cutter G; Marrie RA
    Mult Scler Relat Disord; 2019 Jun; 31():165-172. PubMed ID: 31063935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of fatigue, depression and the level of disability on the health-related quality of life of glatiramer acetate-treated relapsing-remitting patients with multiple sclerosis in Hungary.
    Fricska-Nagy Z; Füvesi J; Rózsa C; Komoly S; Jakab G; Csépány T; Jobbágy Z; Lencsés G; Vécsei L; Bencsik K
    Mult Scler Relat Disord; 2016 May; 7():26-32. PubMed ID: 27237753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study.
    Jongen PJ; Lehnick D; Sanders E; Seeldrayers P; Fredrikson S; Andersson M; Speck J;
    Health Qual Life Outcomes; 2010 Nov; 8():133. PubMed ID: 21078142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Employment and absenteeism in working-age persons with multiple sclerosis.
    Salter A; Thomas N; Tyry T; Cutter G; Marrie RA
    J Med Econ; 2017 May; 20(5):493-502. PubMed ID: 28035846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of multiple sclerosis relapse: The NARCOMS participant perspective.
    Nickerson M; Cofield SS; Tyry T; Salter AR; Cutter GR; Marrie RA
    Mult Scler Relat Disord; 2015 May; 4(3):234-40. PubMed ID: 26008940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue-Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers.
    Neuhaus O; Köhler W; Then Bergh F; Kristoferitsch W; Faiss J; Rosenkranz T; Reske D; Patejdl R; Hartung HP; Zettl UK
    Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33800033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relations between mood characteristics, circadian preferences, and functionality in multiple sclerosis.
    Ozdemir PG; Milanlioglu A; Boysan M; Cilingir V; Aydin N; Atli A
    Int J Psychiatry Clin Pract; 2015 Jun; 19(2):148-54. PubMed ID: 25363199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of multiple sclerosis symptoms across lifespan: data from the NARCOMS Registry.
    Fox RJ; Bacon TE; Chamot E; Salter AR; Cutter GR; Kalina JT; Kister I
    Neurodegener Dis Manag; 2015; 5(6 Suppl):3-10. PubMed ID: 26611264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender differences in self-reported symptom awareness and perceived ability to manage therapy with disease-modifying medication among commercially insured multiple sclerosis patients.
    Vlahiotis A; Sedjo R; Cox ER; Burroughs TE; Rauchway A; Lich R
    J Manag Care Pharm; 2010 Apr; 16(3):206-16. PubMed ID: 20331325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.